maribavir
General
Pronunciation: 
ma-rye-ba-vir
Trade Name(s)
- Livtencity
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Maribavir." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580062/all/maribavir. 
Vallerand AHA, Sanoski CAC,  . Maribavir. Davis's Drug Guide. F.A. Davis Company; 2025. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580062/all/maribavir. Accessed October 30, 2025.
Vallerand, A. H., Sanoski, C. A., & ,  (2025). Maribavir. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580062/all/maribavir
Vallerand AHA, Sanoski CAC,  . Maribavir [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 October 30]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580062/all/maribavir.
* Article titles in AMA citation format should be in sentence-case
TY  -  ELEC
T1  -  maribavir
ID  -  3580062
A1  -  Sanoski,Cynthia A,
AU  -  Vallerand,April Hazard,
AU  -  ,,
BT  -  Davis's Drug Guide
UR  -  https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580062/all/maribavir
PB  -  F.A. Davis Company
ET  -  19
DB  -  Nursing Central
DP  -  Unbound Medicine
ER  -  

 Davis's Drug Guide
Davis's Drug Guide

